Cargando…

Coexistent Breast Cancer and Essential Thrombocythemia: How We Addressed the Therapeutic Challenges

Essential thrombocythemia (ET) occurring with breast cancer is uncommon; the therapeutic approach varies and poses a challenge. A 65-year-old female presented to us after being diagnosed with hormone positive, HER2-negative infiltrating ductal carcinoma. She had a platelet count of 600 thou/cu mm. H...

Descripción completa

Detalles Bibliográficos
Autores principales: Seegobin, Karan, Gharia, Bharatsinh, Maharaj, Satish, Zuberi, Lara
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6109582/
https://www.ncbi.nlm.nih.gov/pubmed/30159181
http://dx.doi.org/10.1155/2018/2080185
_version_ 1783350353803083776
author Seegobin, Karan
Gharia, Bharatsinh
Maharaj, Satish
Zuberi, Lara
author_facet Seegobin, Karan
Gharia, Bharatsinh
Maharaj, Satish
Zuberi, Lara
author_sort Seegobin, Karan
collection PubMed
description Essential thrombocythemia (ET) occurring with breast cancer is uncommon; the therapeutic approach varies and poses a challenge. A 65-year-old female presented to us after being diagnosed with hormone positive, HER2-negative infiltrating ductal carcinoma. She had a platelet count of 600 thou/cu mm. Her JAK2 mutation was positive. Bone marrow biopsy showed increased megakaryocytes. She was diagnosed with ET in the setting of breast cancer. She underwent breast conservation surgery after which aspirin was resumed. Anticipating thrombocytopenia during chemotherapy and given the absence of data combining hydroxyurea with standard chemotherapy used for breast cancer, we felt it prudent to delay cytoreductive therapy for her ET until after completion of breast cancer treatment. Her average platelet count during chemotherapy was 480 thou/cu mm with the lowest being 377 thou/cu mm. Her platelet count remained at goal between 300 and 350 thou/cu mm after four months of hydroxyurea.
format Online
Article
Text
id pubmed-6109582
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Hindawi
record_format MEDLINE/PubMed
spelling pubmed-61095822018-08-29 Coexistent Breast Cancer and Essential Thrombocythemia: How We Addressed the Therapeutic Challenges Seegobin, Karan Gharia, Bharatsinh Maharaj, Satish Zuberi, Lara Case Rep Hematol Case Report Essential thrombocythemia (ET) occurring with breast cancer is uncommon; the therapeutic approach varies and poses a challenge. A 65-year-old female presented to us after being diagnosed with hormone positive, HER2-negative infiltrating ductal carcinoma. She had a platelet count of 600 thou/cu mm. Her JAK2 mutation was positive. Bone marrow biopsy showed increased megakaryocytes. She was diagnosed with ET in the setting of breast cancer. She underwent breast conservation surgery after which aspirin was resumed. Anticipating thrombocytopenia during chemotherapy and given the absence of data combining hydroxyurea with standard chemotherapy used for breast cancer, we felt it prudent to delay cytoreductive therapy for her ET until after completion of breast cancer treatment. Her average platelet count during chemotherapy was 480 thou/cu mm with the lowest being 377 thou/cu mm. Her platelet count remained at goal between 300 and 350 thou/cu mm after four months of hydroxyurea. Hindawi 2018-08-12 /pmc/articles/PMC6109582/ /pubmed/30159181 http://dx.doi.org/10.1155/2018/2080185 Text en Copyright © 2018 Karan Seegobin et al. http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Case Report
Seegobin, Karan
Gharia, Bharatsinh
Maharaj, Satish
Zuberi, Lara
Coexistent Breast Cancer and Essential Thrombocythemia: How We Addressed the Therapeutic Challenges
title Coexistent Breast Cancer and Essential Thrombocythemia: How We Addressed the Therapeutic Challenges
title_full Coexistent Breast Cancer and Essential Thrombocythemia: How We Addressed the Therapeutic Challenges
title_fullStr Coexistent Breast Cancer and Essential Thrombocythemia: How We Addressed the Therapeutic Challenges
title_full_unstemmed Coexistent Breast Cancer and Essential Thrombocythemia: How We Addressed the Therapeutic Challenges
title_short Coexistent Breast Cancer and Essential Thrombocythemia: How We Addressed the Therapeutic Challenges
title_sort coexistent breast cancer and essential thrombocythemia: how we addressed the therapeutic challenges
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6109582/
https://www.ncbi.nlm.nih.gov/pubmed/30159181
http://dx.doi.org/10.1155/2018/2080185
work_keys_str_mv AT seegobinkaran coexistentbreastcancerandessentialthrombocythemiahowweaddressedthetherapeuticchallenges
AT ghariabharatsinh coexistentbreastcancerandessentialthrombocythemiahowweaddressedthetherapeuticchallenges
AT maharajsatish coexistentbreastcancerandessentialthrombocythemiahowweaddressedthetherapeuticchallenges
AT zuberilara coexistentbreastcancerandessentialthrombocythemiahowweaddressedthetherapeuticchallenges